Phase 3 trials – Page 2

GSK’s Depemokimab Shows Promising Results in Phase 3 Trials, Reducing Asthma Attacks by Half

11 months ago talkbio0Tagged Asthma, Depemokimab, IL-5 Inhibitor, Inflammation, Long-Acting Biologic, Phase 3 trials, Severe (severity modifier), SmithKline Beecham

GSK, Depemokimab, Asthma, Phase 3 Trials, Long-Acting Biologic, IL-5 Inhibitor, Severe Asthma, Type 2 Inflammation

Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials

11 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Hemoglobin A1c measurement, Insulin, insulin therapy, non-inferiority, once-weekly, Phase 3 trials

Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.

Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results

11 months ago talkbio0Tagged development aspects, Invasive Streptococcus pneumoniae disease, Phase 3 trials, Pneumococcal vaccine, Vaccines, VAX-31, Vaxcyte

Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development

Sanofi’s Tolebrutinib Shows Mixed Results in Phase 3 MS Trials, Plans for FDA Filing Remain

11 months ago talkbio0Tagged File (record), Multiple Sclerosis, Phase 3 trials, sanofi, Tolebrutinib, United States Food and Drug Administration

Tolebrutinib, Sanofi, Multiple Sclerosis, Phase 3 Trials, FDA Filing

Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers

11 months ago talkbio0Tagged Early-stage, KEYNOTE-630, KEYNOTE-867, Keytruda, Malignant neoplasm of lung, Malignant neoplasm of skin, Merck, Phase 3 trials

Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630

Ovid Halts Preclinical Work and IV Seizure Program Following Soticlestat’s Phase 3 Setbacks

12 months ago talkbio0Tagged Dosage Forms, Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome, Phase 3 trials, Preclinical, soticlestat, Takeda

Ovid Therapeutics, soticlestat, Phase 3 trials, Dravet syndrome, Lennox-Gastaut syndrome, preclinical work, IV seizure program, Takeda Pharmaceutical

Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials

1 year ago talkbio0Tagged competition, GLP-1/GIP receptor agonist, Market, Obesity, Phase 3 trials, Viking, VK2735, Weight Loss

Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition

Takeda’s Soticlestat Misses Main Goal in Two Pivotal Epilepsy Studies

1 year ago talkbio0Tagged Epilepsy, Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome, Phase 3 trials, Seizures, soticlestat, Takeda, With frequency

Soticlestat, Takeda, Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Phase 3 Trials, Seizure Frequency

AstraZeneca’s Next-Generation Covid Therapy Shines in Phase 3 Trials

1 year ago talkbio0Tagged Antibodies, AstraZeneca, COVID19 (disease), Effectiveness, Evusheld, next-generation therapy, Phase 3 trials, Safety, successor

AstraZeneca, Covid-19, Evusheld, Phase 3 trials, next-generation therapy, successor, antibody treatment, prevention, efficacy, safety.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

1 year ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.